Second-trimester maternal serum invasive trophoblast antigen: a marker for Down syndrome screening.

Immunosuppressive Drug Monitoring. Ther Drug Monit 2002;24:59–67. 12. Novartis. Neoral C-2 monitoring: scientific evidence and clinical validation. http://www.transplantation-schweiz.ch/e/sandimmun/Scientific_Monograph. pdf (accessed June 2004). 13. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonal SP, Mathew TH. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporine at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002;24:479–86. 14. Oellerich M, Armstrong VW. Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy? Ther Drug Monit 2002;24:40–6. 15. Johnston A, Chusney G, Oellerich M, Lee TD, Holt DW. Monitoring cyclosporine in blood: between assay differences at trough and 2 hour post-dose (C2). Ther Drug Monit 2003;25:167–73. 16. Strologo LD, Ponstesilli C, Rizzoni G. C2 monitoring: a reliable tool in pediatric renal transplant recipients. Transplantation 2003;76:444–5. 17. Holt DW, Johnston A, Kahan BD, Morris RG, Oellerich M, Shaw LM. New approaches to cyclosporine monitoring raise further concerns about analytical techniques. Clin Chem 2000;46:872–4. 18. Abbott Laboratories. TDxFLx cyclosporine monoclonal whole blood. Package insert 9797-60 E 34-0060/R7. Abbott Park, IL: Abbott Laboratories, 2001: 1–6.